Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells

Authors: Linnéa Eriksson, Özlem Erdogdu, Thomas Nyström, Qimin Zhang, Åke Sjöholm

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

The leading cause of death for patients suffering from diabetes is macrovascular disease. Endothelial dysfunction is often observed in type 2 diabetic patients and it is considered to be an important early event in the pathogenesis of atherogenesis and cardiovascular disease. Many drugs are clinically applied to treat diabetic patients. However, little is known whether these agents directly interfere with endothelial cell proliferation and apoptosis. This study therefore aimed to investigate how anti-diabetic and cardioprotective agents affect human coronary artery endothelial cells (HCAECs).

Methods

The effect of anti-diabetic and cardioprotective agents on HCAEC viability, proliferation and apoptosis was studied. Viability was assessed using Trypan blue exclusion; proliferation in 5 mM and 11 mM of glucose was analyzed using [3H]thymidine incorporation. Lipoapoptosis of the cells was investigated by determining caspase-3 activity and the subsequent DNA fragmentation after incubation with the free fatty acid palmitate, mimicking diabetic lipotoxicity.

Results

Our data show that insulin, metformin, BLX-1002, and rosuvastatin improved HCAEC viability and they could also significantly increase cell proliferation in low glucose. The proliferative effect of insulin and BLX-1002 was also evident at 11 mM of glucose. In addition, insulin, metformin, BLX-1002, pioglitazone, and candesartan significantly decreased the caspase-3 activity and the subsequent DNA fragmentation evoked by palmitate, suggesting a protective effect of the drugs against lipoapoptosis.

Conclusion

Our results suggest that the anti-diabetic and cardioprotective agents mentioned above have direct and beneficial effects on endothelial cell viability, regeneration and apoptosis. This may add yet another valuable property to their therapeutic effect, increasing their clinical utility in type 2 diabetic patients in whom endothelial dysfunction is a prominent feature that adversely affect their survival.
Appendix
Available only for authorised users
Literature
1.
Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010, 87 (1): 4-14. 10.1016/j.diabres.2009.10.007.CrossRefPubMed
2.
Sjoholm A, Nystrom T: Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006, 22 (1): 4-10. 10.1002/dmrr.568.CrossRefPubMed
3.
Sjoholm A, Nystrom T: Endothelial inflammation in insulin resistance. Lancet. 2005, 365 (9459): 610-612.CrossRefPubMed
4.
Dandona P, Ghanim H, Chaudhuri A, Mohanty P: Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J Diabetes Complications. 2008, 22 (1): 62-75. 10.1016/j.jdiacomp.2006.10.009.CrossRefPubMed
5.
Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001, 22 (1): 36-52. 10.1210/er.22.1.36.CrossRefPubMed
6.
Avogaro A, de Kreutzenberg SV, Fadini G: Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract. 2008, 82 (Suppl 2): S94-S101.CrossRefPubMed
7.
Rask-Madsen C, King GL: Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007, 3 (1): 46-56. 10.1038/ncpendmet0366.CrossRefPubMed
8.
Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996, 97 (11): 2601-2610. 10.1172/JCI118709.PubMedCentralCrossRefPubMed
9.
Nathanson D, Nystrom T: Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Mol Cell Endocrinol. 2009, 297 (1-2): 112-126. 10.1016/j.mce.2008.11.016.CrossRefPubMed
10.
Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA: Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res. 2002, 90 (1): 107-111. 10.1161/hh0102.102359.CrossRefPubMed
11.
Lundman P, Tornvall P, Nilsson L, Pernow J: A triglyceride-rich fat emulsion and free fatty acids but not very low density lipoproteins impair endothelium-dependent vasorelaxation. Atherosclerosis. 2001, 159 (1): 35-41. 10.1016/S0021-9150(01)00478-6.CrossRefPubMed
12.
Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY: High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation. 2000, 101 (22): 2618-2624.CrossRefPubMed
13.
Chai W, Liu Z: p38 mitogen-activated protein kinase mediates palmitate-induced apoptosis but not inhibitor of nuclear factor-kappaB degradation in human coronary artery endothelial cells. Endocrinology. 2007, 148 (4): 1622-1628.CrossRefPubMed
14.
Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P: C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia. 2011, 54 (10): 2702-2712. 10.1007/s00125-011-2251-0.CrossRefPubMed
15.
Hamaguchi T, Hirose T, Asakawa H, Itoh Y, Kamado K, Tokunaga K, Tomita K, Masuda H, Watanabe N, Namba M: Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide. Diabetes Res Clin Pract. 2004, 66 (Suppl 1): S129-S132.CrossRefPubMed
16.
Smith U: Pioglitazone: mechanism of action. Int J Clin Pract Suppl. 2001, 121: 13-18.PubMed
17.
Matsumoto N, Manabe H, Ochiai J, Fujita N, Takagi T, Uemura M, Naito Y, Yoshida N, Oka S, Yoshikawa T: An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity. Shock. 2003, 19 (6): 547-552. 10.1097/01.shk.0000070734.34700.80.CrossRefPubMed
18.
Li X, Yang G, Zhao G, Wu B, Edin ML, Zeldin DC, Wang DW: Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertens Res. 2011, 34 (7): 869-875. 10.1038/hr.2011.44.PubMedCentralCrossRefPubMed
19.
Brunmair B, Staniek K, Lehner Z, Dey D, Bolten CW, Stadlbauer K, Luger A, Furnsinn C: Lipophilicity as a determinant of thiazolidinedione action in vitro: findings from BLX-1002, a novel compound without affinity to PPARs. Am J Physiol Cell Physiol. 2011, 300 (6): C1386-C1392. 10.1152/ajpcell.00401.2010.CrossRefPubMed
20.
Zhang F, Dey D, Branstrom R, Forsberg L, Lu M, Zhang Q, Sjoholm A: BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol. 2009, 296 (2): C346-C354.CrossRefPubMed
21.
Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, et al: Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes. 2004, 53 (4): 1052-1059. 10.2337/diabetes.53.4.1052.CrossRefPubMed
22.
Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q: Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2009, 325 (1-2): 26-35.CrossRef
23.
Edwards SJ, Reader KL, Lun S, Western A, Lawrence S, McNatty KP, Juengel JL: The cooperative effect of growth and differentiation factor-9 and bone morphogenetic protein (BMP)-15 on granulosa cell function is modulated primarily through BMP receptor II. Endocrinology. 2008, 149 (3): 1026-1030.CrossRefPubMed
24.
Sjoholm A, Zhang Q, Welsh N, Hansson A, Larsson O, Tally M, Berggren PO: Rapid Ca2+ influx and diacylglycerol synthesis in growth hormone-mediated islet beta -cell mitogenesis. J Biol Chem. 2000, 275 (28): 21033-21040. 10.1074/jbc.M001212200.CrossRefPubMed
25.
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995, 376 (6535): 37-43. 10.1038/376037a0.CrossRefPubMed
26.
Kageyama S, Yokoo H, Tomita K, Kageyama-Yahara N, Uchimido R, Matsuda N, Yamamoto S, Hattori Y: High glucose-induced apoptosis in human coronary artery endothelial cells involves up-regulation of death receptors. Cardiovasc Diabetol. 2011, 10: 73-10.1186/1475-2840-10-73.PubMedCentralCrossRefPubMed
27.
Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N: Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol. 2011, 10: 105-10.1186/1475-2840-10-105.PubMedCentralCrossRefPubMed
28.
Varma S, Lal BK, Zheng R, Breslin JW, Saito S, Pappas PJ, Hobson RW, Duran WN: Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol. 2005, 289 (4): H1744-H1751. 10.1152/ajpheart.01088.2004.PubMedCentralCrossRefPubMed
29.
McGinn S, Saad S, Poronnik P, Pollock CA: High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am J Physiol Endocrinol Metab. 2003, 285 (4): E708-E717.CrossRefPubMed
30.
Berk BC, Abe JI, Min W, Surapisitchat J, Yan C: Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci. 2001, 947: 93-109. discussion 109-111CrossRefPubMed
31.
Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R: Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007, 115 (18): 2435-2441. 10.1161/CIRCULATIONAHA.107.693739.CrossRefPubMed
32.
Nickson CM, Doherty PJ, Williams RL: Novel polymeric coatings with the potential to control in-stent restenosis-an in vitro study. J Biomater Appl. 2010, 24 (5): 437-452. 10.1177/0885328208099338.CrossRefPubMed
33.
Gousseva N, Kugathasan K, Chesterman CN, Khachigian LM: Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J Cell Biochem. 2001, 81 (3): 523-534. 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E.CrossRefPubMed
34.
Enomoto S, Sata M, Fukuda D, Nakamura K, Nagai R: Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. Biomed Pharmacother. 2009, 63 (1): 19-26. 10.1016/j.biopha.2007.11.002.CrossRefPubMed
35.
Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006, 7 (8): 606-619. 10.1038/nrg1879.CrossRefPubMed
36.
Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000, 101 (13): 1539-1545.CrossRefPubMed
37.
Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006, 55 (2): 496-505. 10.2337/diabetes.55.02.06.db05-1064.CrossRefPubMed
38.
Piro S, Spampinato D, Spadaro L, Oliveri CE, Purrello F, Rabuazzo AM: Direct apoptotic effects of free fatty acids on human endothelial cells. Nutr Metab Cardiovasc Dis. 2008, 18 (2): 96-104. 10.1016/j.numecd.2007.01.009.CrossRefPubMed
39.
Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S: Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000, 20 (2): 402-409. 10.1161/01.ATV.20.2.402.CrossRefPubMed
40.
Franke TF, Kaplan DR, Cantley LC: PI3K: downstream AKTion blocks apoptosis. Cell. 1997, 88 (4): 435-437. 10.1016/S0092-8674(00)81883-8.CrossRefPubMed
41.
Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ, Park SY: AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci. 2008, 106 (3): 394-403. 10.1254/jphs.FP0071857.CrossRefPubMed
42.
Artwohl M, Holzenbein T, Furnsinn C, Freudenthaler A, Huttary N, Waldhausl WK, Baumgartner-Parzer SM: Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost. 2005, 93 (5): 810-815.PubMed
43.
Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M, Laufs U: The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007, 192 (1): 67-74. 10.1016/j.atherosclerosis.2006.06.026.CrossRefPubMed
44.
Fujisawa K, Nishikawa T, Kukidome D, Imoto K, Yamashiro T, Motoshima H, Matsumura T, Araki E: TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun. 2009, 379 (1): 43-48. 10.1016/j.bbrc.2008.11.141.CrossRefPubMed
45.
Chen J, Li D, Zhang X, Mehta JL: Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone. J Cardiovasc Pharmacol Ther. 2004, 9 (1): 35-41. 10.1177/107424840400900i106.CrossRefPubMed
Metadata
Title
Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells
Authors
Linnéa Eriksson
Özlem Erdogdu
Thomas Nyström
Qimin Zhang
Åke Sjöholm
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-27

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue

Original investigation

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

Original investigation

Latent associations of low serum amylase with decreased plasma insulin levels and insulin resistance in asymptomatic middle-aged adults

Original investigation

Characteristics of poorly controlled Type 2 diabetes patients in Swiss primary care

Original investigation

Expression of fourteen novel obesity-related genes in zucker diabetic fatty rats

Original investigation

Efficacy of endoluminal interventional therapy in diabetic peripheral arterial occlusive disease: a retrospective trial

Original investigation

A retrospective analysis of amputation rates in diabetic patients: can lower extremity amputations be further prevented?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits